Cargando…
AB110. Efficacy and safety of mTOR inhibitor in the treatment of renal cell cancer: a meta-analysis
BACKGROUND: Treatment for metastatic renal cell cancer (mRCC) has advanced dramatically with understanding of the pathogenesis of the disease. New treatment options may provide improved median progression-free survival (MPFS). We aimed to determine the relative effectiveness of new therapies in this...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708334/ http://dx.doi.org/10.3978/j.issn.2223-4683.2014.s110 |